INTRODUCTION: There is a strong impetus for the use of telemedicine for boosting early detection rates and enabling early treatment and remote monitoring of COVID-19 cases, particularly in chronically ill patients such as kidney transplant recipients (KTRs). However, data regarding the effectiveness of this practice are lacking. METHODS: In this retrospective, observational study with prospective data gathering we analyzed the outcomes of all confirmed COVID-19 cases (n = 955) in KTRs followed at our center between March 1, 2020, and April 30, 2022. Risk factors of COVID-19 related mortality were analyzed with focus on the role of early referral to the transplant center, which enabled early initiation of treatment and remote outpatient management. This proactive approach was dependent on the establishment and use of a telemedicine system, which facilitated patient-physician communication and expedited diagnostics and treatment. The main exposure evaluated was early referral of KTRs to the transplantation center after confirmed or suspected COVID-19 infection. The primary outcome was the association of early referral to the transplantation center with the risk of death within 30 days following a COVID-19 diagnosis, evaluated by logistic regression. RESULTS: We found that KTRs who referred their illness to the transplant center late had a higher 30-day mortality (4.5 vs. 13.6%, p < 0.001). Thirty days mortality after the diagnosis of COVID-19 was independently associated with late referral to the transplant center (OR 2.08, 95% CI 1.08-3.98, p = 0.027), higher age (OR 1.09, 95% CI 1.05-1.13, p < 0.001), higher body mass index (OR 1.06, 95% CI 1.01-1.12, p = 0.03), and lower eGFR (OR 0.96, 95% CI 0.94-0.98, p < 0.001) in multivariable logistic regression. Furthermore, KTRs who contacted the transplant center late were older, had longer time from transplantation, lived farther from the center and presented with higher Charlson comorbidity index. DISCUSSION: A well-organized telemedicine program can help to protect KTRs during an infectious disease outbreak by facilitating pro-active management and close surveillance. Furthermore, these results can be likely extrapolated to other vulnerable populations, such as patients with chronic kidney disease, diabetes or autoimmune diseases requiring the use of immunosuppression.

Department of Information Technology Institute for Clinical and Experimental Medicine Prague Czechia

Department of Nephrology Institute for Clinical and Experimental Medicine Prague Czechia

Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czechia

See more in PubMed

Ao G, Wang Y, Qi X, Nasr B, Bao M, Gao M, et al. . The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis. Transplant Rev. (2021) 35:100628. doi: 10.1016/j.trre.2021.100628, PMID: PubMed DOI PMC

Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. . Factors associated with COVID-19-related death using OpenSAFELY. Nature. (2020) 584:430–6. doi: 10.1038/s41586-020-2521-4, PMID: PubMed DOI PMC

Schold JD, King KL, Husain SA, Poggio ED, Buccini LD, Mohan S. COVID-19 mortality among kidney transplant candidates is strongly associated with social determinants of health. Am J Transplant. (2021) 21:2563–72. doi: 10.1111/ajt.16578, PMID: PubMed DOI PMC

Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with SARS-CoV-2 omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nat Med. (2022) 28:1933–43. doi: 10.1038/s41591-022-01887-z, PMID: PubMed DOI PMC

Cochran W, Shah P, Barker L, Langlee J, Freed K, Boyer L, et al. . COVID-19 clinical outcomes in solid organ transplant recipients during the omicron surge. Transplantation. (2022) 106:e346–7. doi: 10.1097/TP.0000000000004162, PMID: PubMed DOI PMC

McMahan K, Giffin V, Tostanoski LH, Chung B, Siamatu M, Suthar MS, et al. . Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. Med. (2022) 3:262–268.e4. doi: 10.1016/j.medj.2022.03.004, PMID: PubMed DOI PMC

Marani M, Katul GG, Pan WK, Parolari AJ. Intensity and frequency of extreme novel epidemics. Proc Natl Acad Sci U S A. (2021) 118:e2105482118. doi: 10.1073/pnas.2105482118, PMID: PubMed DOI PMC

Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, et al. . Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. (2000) 11:S1–S86. doi: 10.1681/ASN.V11suppl_1s1 PubMed DOI

Connor A, Mortimer F, Higgins R. The follow-up of renal transplant recipients by telephone consultation: three years experience from a single UK renal unit. Clin Med. (2011) 11:242–6. doi: 10.7861/clinmedicine.11-3-242 PubMed DOI PMC

Institute of Medicine, Committee on Evaluating Clinical Applications of Telemedicine . Telemedicine: a guide to assessing telecommunications for health care. Washington, DC: National Academies Press; (1996). PubMed

Institute of Medicine (US) . Committee on evaluating clinical applications of telemedicine In: Field MJ, editor. Telemedicine: a guide to assessing telecommunications in health care. Washington, DC: National Academies Press (US) (1996) PubMed

Institute for Clinical and Experimental Medicine . Online IKEM—smart app. (2023). Available at: https://www.online.ikem.cz

Komenda M, Bulhart V, Karolyi M, Jarkovský J, Mužík J, Májek O, et al. . Complex reporting of the COVID-19 epidemic in the Czech Republic: use of an interactive web-based app in practice. J Med Internet Res. (2020) 22:e19367. doi: 10.2196/19367, PMID: PubMed DOI PMC

Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom. (2022) 91:8–35. doi: 10.1159/000521288, PMID: PubMed DOI

Whitaker M, Elliott J, Bodinier B, Barclay W, Ward H, Cooke G, et al. . Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat Commun. (2022) 13:6856. doi: 10.1038/s41467-022-34244-2, PMID: PubMed DOI PMC

Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants—clinical, public health, and vaccine implications. N Engl J Med. (2021) 384:1866–8. doi: 10.1056/NEJMc2100362, PMID: PubMed DOI PMC

Aguilar RB, Hardigan P, Mayi B, Sider D, Piotrkowski J, Mehta JP, et al. . Current understanding of COVID-19 clinical course and investigational treatments. Front Med. (2020) 7:555301. doi: 10.3389/fmed.2020.555301, PMID: PubMed DOI PMC

Akhmerov A, Marbán E. COVID-19 and the heart. Circ Res. (2020) 126:1443–55. doi: 10.1161/CIRCRESAHA.120.317055 PubMed DOI PMC

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. (1987) 40:373–83. doi: 10.1016/0021-9681(87)90171-8, PMID: PubMed DOI

National Institutes of Health. COVID-19 Treatment Guidelines Panel . Coronavirus disease 2019 (COVID-19) treatment guidelines NIH; (2022) Available at: https://www.covid19treatmentguidelines.nih.gov/. PubMed

Long L, Wu L, Chen L, Zhou D, Wu H, Lu D, et al. . Effect of early oxygen therapy and antiviral treatment on disease progression in patients with COVID-19: a retrospective study of medical charts in China. PLoS Negl Trop Dis. (2021) 15:e0009051. doi: 10.1371/journal.pntd.0009051, PMID: PubMed DOI PMC

Kow CS, Ramachandram DS, Hasan SS. Early oxygen therapy may be beneficial to patients with COVID-19 and underlying pulmonary diseases. J Asthma. (2022) 60:422–3. doi: 10.1080/02770903.2022.2056701 PubMed DOI

Sun Q, Qiu H, Huang M, Yang Y. Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province. Ann Intensive Care. (2020) 10:33. doi: 10.1186/s13613-020-00650-2, PMID: PubMed DOI PMC

Hettle D, Hutchings S, Muir P, Moran E, COVID-19 Genomics UK (COG-UK) consortium . Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: retrospective cohort study and literature review. Clin Infect Pract. (2022) 16:100210. doi: 10.1016/j.clinpr.2022.100210, PMID: PubMed DOI PMC

The Transplantation Society . Guidance on coronavirus disease 2019 (COVID-19) for transplant clinicians TTS; (2022) Available at: https://tts.org/23-tid/tid-news/657-tid-update-and-guidance-on-2019-novel-coronavirus-2019-ncov-for-transplant-id-clinicians.

Lam K, Lu AD, Shi Y, Covinsky KE. Assessing telemedicine unreadiness among older adults in the United States during the COVID-19 pandemic. JAMA Intern Med. (2020) 180:1389–91. doi: 10.1001/jamainternmed.2020.2671, PMID: PubMed DOI PMC

Zahradka I, Petr V, Magicova M, Viklicky O. Background risk should be taken into account when reporting vaccine effectiveness. Am J Transplant. (2022) 22:1927–8. doi: 10.1111/ajt.16961 PubMed DOI

Zahradka I, Petr V, Modos I, Magicova M, Dusek L, Viklicky O. Association between SARS-CoV-2 messenger RNA vaccines and lower infection rates in kidney transplant recipients: a registry-based report. Ann Intern Med. (2022) 175:961–8. doi: 10.7326/M21-2973 PubMed DOI PMC

Aslam S, Adler E, Mekeel K, Little SJ. Clinical effectiveness of COVID‐19 vaccination in solid organ transplant recipients. Transpl Infect Dis. (2021) 23:e13705. doi: 10.1111/tid.13705 PubMed DOI PMC

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine Booster Doses in Kidney Transplant Recipients: Results of a 12-mo Follow-up From a Prospective Observational Study